300937 Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical
WatchlistSichuan Hezong Medicine Easy-To-Buy Pharmaceutical News
Pharmaceutical Easy Purchase (300937.SZ): Tianwen reduced its shares by 1.26% by a total of 1.26%
On November 27, Gelonghui (300937.SZ) announced that it recently received the “Notice Letter on Reducing the Shares of Sichuan Hezong Pharmaceutical Co., Ltd. by a total of 1% and the progress of the reduction” issued by Mr. Tian Wenshu, a shareholder holding at least 5% of the company's shares and supervisor. It was learned that Mr. Tian Wenwen reduced his holdings of the company's shares by a total of 1,203,095 shares through centralized bidding between July 19, 2023 and November 24, 2023. The reduction in shareholding accounts for 1.26% of the company's total share capital.
The specific shareholders of Chengdu Boyuan Singapore Airlines and co-actors of Pharmaceutical E-Buy (300937.SZ) reduced their shares by a total of 1.04%
Pharmaceutical Easy Purchase (300937.SZ) issued an announcement. The company recently received the Chengdu Boyuan Singapore Airlines Venture Capital Fund from a specific shareholder...
Pharmaceutical Easy Buy (300937.SZ) plans to increase capital and change its name to Chengdu Pharmaceutical Easy Buy and establish a new subsidiary in Zhengzhou
Pharmaceutical E-Buy (300937.SZ) announcement. The previous announcement revealed that the company plans to establish Sichuan Pharmaceutical E-Buy Technology Group Co., Ltd...
[BT Financial Report Instantaneous Analysis] Pharmaceutical Tesco 2023 Quarterly Report: Net profit has increased dramatically, and the out-of-hospital market has become the main growth point
This financial report was announced on 2023-10-27 19:57:42 Pharmaceutical E-Commerce (stock code: 300937) is an enterprise that plays an important role in the pharmaceutical distribution industry, providing drug sales and distribution services to consumers. As health reform policies deepen and people pay more attention to healthy living, the pharmaceutical distribution market has ushered in new development opportunities. Drug E-Buy plays an important role in this industry, providing drug sales and distribution services to consumers. In terms of assets and liabilities, E-Pharma's total assets for the third quarter of 2023 were 1,625 billion yuan, compared to 15 at the end of the previous year.
Pharmaceutical Easy Buy (300937.SZ) released the first three quarter results, net profit of 50,1573 million yuan, an increase of 198.95%
Pharmaceutical Easy Buy (300937.SZ) released its report for the third quarter of 2023, achieving revenue of 32.1 in the first three quarters...
Tesco (300937. SZ) plans to invest 42 million yuan in the Huzhou Jiansu Pharmaceutical Tesco Fund to lay out major medical and health sectors
Tesco (300937.SZ) announced that the company intends to participate in the Huzhou Jiansu Tesco venture capital as a limited partner...
Tesco (300937.SZ): It is proposed to establish a wholly-owned subsidiary, Sichuan Tesco Technology Group
GLONGHUI, Oct. 13丨Tesco Pharmaceutical (300937.SZ) announced that on October 13, 2023, Sichuan Hezong Pharmaceutical Co., Ltd. held the 15th meeting of the 3rd board of directors to deliberate and pass the “Proposal on Investing in Establishing Wholly-owned Subsidiaries”. The board of directors agreed that the company will jointly invest with its wholly-owned subsidiary Chengdu Heshengyi Technology Co., Ltd. to establish a wholly-owned subsidiary, Sichuan Yaoyisheng Technology Group Co., Ltd., based on the needs of business planning and business development. The registered capital is RMB 1177.77.
Tesco: Some amounts in the company's individual bank accounts have been frozen
GLONGHUI, September 14 | Tesco announced that recently, through bank inquiries, it was learned that the funds in the company's two bank accounts have been frozen. Up to now, the company has not received judicial documents such as court execution rulings. As of the disclosure date of the announcement, the actual amount frozen by the company was 58,194,688.48 yuan, accounting for 7.15% of the company's most recent audited net assets; the maximum amount frozen was 99,294,293.84 yuan, accounting for 12.20% of the company's most recent audited net assets.
The pharmaceutical commercial sector boosted the rise and suspension of Tesco
Gelonghui, August 23 | Tesco rose and stopped by 20cm. Chinese Health, Kaikai Industrial, First Pharmaceutical, Zhejiang Zhenyuan, and Shu Yu Civilian went up one after another.
SPD concept stock boosts Pharmaceutical Tesco by more than 10%
Gelonghui, August 23 | Tesco Pharmaceutical rose more than 10%, followed by Chinese Health, Kaikai Industrial, First Pharmaceutical, Zhejiang Zhenyuan, and Celi Medical.
Changes in A-shares | Tesco surged more than 16%, and medium-term net profit increased more than fivefold year-on-year
Gelonghui, August 23 | Tesco (300937.SZ) has risen sharply by more than 16%. It is currently reported at 3.817 yuan, with a total market value of 3.7 billion yuan. The company announced last night that revenue for the first half of the year was 2.205 billion yuan, an increase of 25.4% over the previous year; Guimu's net profit was 467.177 million yuan, an increase of 540.72% over the previous year. The company continues to expand and optimize various resources and upstream and downstream channels.
Tesco (300937.SZ): Net profit increased by 540.72% in the first half of the year to 467.177 million yuan
GLONGHUI, August 22丨Tesco (300937.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 2.205 billion yuan, up 25.40% year on year; net profit attributable to shareholders of listed companies was 467.177 million yuan, up 540.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 44.1632 million yuan, up 994.04% year on year; basic earnings per share were 0.49 yuan.
Medicinal Tesco (300937.SZ): Chengdu Boyuan Singapore Airlines and Co-Actors have reduced their shareholding by a total of 1.04%
GLONGHUI, August 11丨Medicinal Tesco (300937.SZ) announced that the company recently received the “Notice on Reducing the Shares of Sichuan Joint Pharmaceutical Tesco Pharmaceutical Co., Ltd. by more than half of the time and progress of holdings reduction” issued by Chengdu Boyuan Singapore Airlines, co-actors, Sichuan Hite Airlines, and Chengdu Boyuan Tianhong. As of August 10, 2023, the shareholders' holdings reduction plan was over half of the time, and a total of 996,200 shares had been reduced through centralized bidding, accounting for 1.04% of the company's total share capital.
Chengdu Boyuan Xinhang, a shareholder of Medicinal Tesco (300937.SZ) and co-actors reduced their holdings by 996,200 shares over half of the holdings reduction period
According to the Zhitong Finance App, Medicinal Tesco (300937.SZ) announced that the company's shareholders, Chengdu Boyuan New Airlines, the co-actors, Sichuan Hite Airlines, and Chengdu Boyuan Tianhong have already halfway through the plan to reduce their holdings, totaling 996,200 shares of the company's shares.
Medicinal Tesco (300937.SZ): The current pharmaceutical restructuring will not have an impact on the company
GLONGHUI August 9丨Some investors asked Tesco (300937.SZ), “Did the company's semi-annual performance increase mainly benefit from what factors? Will the ongoing pharmaceutical restructuring have a positive impact on the company?” Medicinal Tesco replied that the company's semi-annual performance growth mainly benefited from the company's business development. The company has disclosed the main reason for the anticipated increase in the current period's performance in the “2023 Semi-Annual Performance Forecast”. The company will disclose the details of the current period's business performance in the 2023 semi-annual report, so stay tuned. The current pharmaceutical restructuring will have no impact on the company.
Medicinal Tesco (300937.SZ): Plans to transfer 80% of the shares of Sichuan Hezong Chinese Medicine Tablets
On July 27, GLONGHUI | Medicinal Tesco (300937.SZ) announced that the company plans to transfer 80% of its shares in Sichuan Hechong Chinese Medicine Tablet Co., Ltd. (hereinafter referred to as the “target company”) to Sichuan Zhonghuisheng Chinese Herbal Medicine Partnership (Limited Partnership). The share transfer transaction price is RMB 6.71968 million. After the equity transfer is completed, the company still holds 12.50% of the shares in the underlying company, and the underlying company will no longer be included in the scope of the company's consolidated statements.
Medicinal Tesco (300937.SZ): It has built its own direct distribution logistics system and has set up independent operation of Medicinal Easy Logistics
GLONGHUI July 26丨Some investors asked Tesco (300937.SZ), “Does the company cooperate in supplying primary care institutions and pharmacies? Does the company have its own logistics? Whether to consider investing in logistics, like “Nationwide expansion,” Tesco replied that since its establishment, the company has been focusing on omnichannel pharmaceutical services, and the company covers customers including community pharmaceutical terminals, primary care institutions, etc. The company has built its own direct distribution logistics system and set up a wholly-owned subsidiary, Yaoyida Logistics, to operate independently. The company will also keep an eye on industry opportunities.
Pharmaceutical Tesco (300937.SZ) Supervisor Tian Wenwen reduced his holdings by a total of 943,000 shares
According to the Zhitong Finance App, Yao Tesco (300937.SZ) announced that Tian Wenwen, the company's supervisor, has reduced his holdings of the company's shares by a total of 943,000 shares, accounting for 0.98% of the total share capital. The number of holdings reduction plans this time is over half.
Medicinal Tesco (300937.SZ) is expected to increase. Net profit for the first half of the year is expected to be 42 million yuan to 50 million yuan, up 476.13% to 585.87% over the previous year
According to the Zhitong Finance App, Medicinal Tesco (300937.SZ) revealed its 2023 semi-annual results forecast. The company expects net profit attributable to shareholders of listed companies in the first half of the year to 42 million yuan to 50 million yuan, up 476.13% to 585.87% year on year; net profit after deducting non-recurring profit and loss is 39 million yuan to 47 million yuan, up 865.35% to 1063.37% year on year. In the first half of 2023, in order to further meet the needs of diversified, large-scale, ecological and platform-based development, the company developed the sector through digital intelligence technology innovation, new industrial model exploration, and sector layout
Tesco: Net profit for the first half of the year is expected to increase 476.13%-585.87%
On July 11, GLONGHUI announced that the company expects net profit of 42 million yuan to 50 million yuan in the first half of 2023, an increase of 476.13%-585.87% over the previous year.